References
- Bui LA, Hurst S, Finch GL, et al. Key considerations in the preclinical development of biosimilars. Drug Discov Today. 2015;20(Suppl 1):3–15.
- US Food and Drug Administration. Biosimilar and interchangeable products. 2020. [cited 2021 Aug 16]. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products.
- Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood. 2014;124(22):3191–3196.
- Schiestl M, Stangler T, Torella C, et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29(4):310–312.
- Planinc A, Dejaegher B, Vander Heyden Y, et al. Batch-to-batch N-glycosylation study of infliximab, trastuzumab and bevacizumab, and stability study of bevacizumab. Eur J Hosp Pharm. 2017;24(5):286–292.
- Windisch J. Biosimilars versus originators: similarities and differences from development to approval. Int J Clin Rheumatol. 2015;10(6):501–510.
- European Medicines Agency Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing monoclonal antibodies—non-clinical and clinical issues. 2014. [cited 2021 Aug 16]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf.
- US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015. [cited 2021 Aug 16]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product.
- McCamish M, Pakulski J, Sattler C, et al. Toward interchangeable biologics. Clin Pharmacol Ther. 2015;97(3):215–217.
- Murdaca G, Gulli R, Spano F, et al. TNF-α gene polymorphisms: association with disease susceptibility and response to anti-TNF-α treatment in psoriatic arthritis. J Invest Dermatol. 2014;134(10):2503–2509.
- Murdaca G, Spano F, Contatore M, et al. Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy. Expert Opin Drug Metab Toxicol. 2014;10(12):1703–1710.
- McBride A, Balu S, Campbell K, et al. Expanded access to cancer treatments from conversion to neutropenia prophylaxis with biosimilar filgrastim-sndz. Future Oncol. 2017;13(25):2285–2295.
- Yoo DH, Choe JY, Shim SC, et al. Switching to biosimilars in the treatment of rheumatic diseases. Expert Rev Clin Immunol. 2018;14(7):557–571.
- Busse A, Lüftner D. What does the pipeline promise about upcoming biosimilar antibodies in oncology? Breast Care. 2019;14(1):10–16.
- Kolberg HC, Colleoni M, Santi P, et al. Totality of scientific evidence in the development of ABP 980, a biosimilar to trastuzumab. Target Oncol. 2019;14(6):647–656.
- Molineux G. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta)®). Curr Pharm Des. 2004;10(11):1235–1244.
- European Medicines Agency Committee for Medicinal Products for Human Use. Assessment report – Ziextenzo. 2018. [cited 2021 Aug 16]. Available from: https://www.ema.europa.eu/en/documents/assessment-report/ziextenzo-epar-public-assessment-report_en.pdf.
- US Food and Drug Administartion. Clinical pharmacology review(s) – Ziextenzo. 2019. [cited 2021 Aug 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/761045Orig1s000ClinPharmR.pdf.
- Kabir ER, Moreino SS, Sharif Siam MK. The breakthrough of biosimilars: a twist in the narrative of biological therapy. Biomolecules. 2019;9(9):410.
- Declerck P, Danesi R, Petersel D, et al. The language of biosimilars: clarification, definitions, and regulatory aspects. Drugs. 2017;77(6):671–677.
- Markus R, Liu J, Ramchandani M, et al. Developing the totality of evidence for biosimilars: regulatory considerations and building confidence for the healthcare community. BioDrugs. 2017;31(3):175–187.
- Thomas M, Thatcher N, Goldschmidt J, et al. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar. Immunotherapy. 2019;11(15):1337–1351.
- Goel N, Chance K. Biosimilars in rheumatology: understanding the rigor of their development. Rheumatology. 2017;56(2):187–197.
- Strand V, Cronstein B. Biosimilars: how similar? Intern Med J. 2014;44(3):218–223.
- Bellon A, Wang J, Skerjanec A, et al. A large multicentre, randomized, double-blind, cross-over study in healthy volunteers to compare pharmacokinetics, pharmacodynamics and safety of a pegfilgrastim biosimilar with its US- and EU-reference biologics. Br J Clin Pharmacol. 2020;86(6):1139–1149.
- Kuribayashi R, Sawanobori K. Current Japanese regulatory systems for generics and biosimilars. J Pharm Sci. 2018;107(3):785–787.
- European Medicines Agency. ICH Topic Q 5 E: comparability of biotechnological/biological products - step 5. 2005. [cited 2021 Aug 16]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-5-e-comparability-biotechnological/biological-products-step-5_en.pdf.
- Nakov R, Gattu S, Wang J, et al. Proposed biosimilar pegfilgrastim shows similarity in pharmacokinetics and pharmacodynamics to reference pegfilgrastim in healthy subjects. Br J Clin Pharmacol. 2018;84(12):2790–2801.
- Yang BB, Morrow PK, Wu X, et al. Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. Cancer Chemother Pharmacol. 2015;75(6):1199–1206.
- Gattu S, Wang J, Bellon A, et al. Meta-analysis of pharmacokinetic/pharmacodynamic results of 3 phase 1 studies with biosimilar pegfilgrastim. Clin Pharmacol Drug Dev. 2021;10(10):1130–1141.
- Blackwell K, Donskih R, Jones CM, et al. A comparison of proposed biosimilar LA-EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: pegfilgrastim randomized oncology (supportive care) trial to evaluate comparative treatment (PROTECT-2), a phase III, randomized, double-blind trial. Oncologist. 2016;21(7):789–794.
- Harbeck N, Lipatov O, Frolova M, et al. Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Future Oncol. 2016;12(11):1359–1367.
- Blackwell K, Gascon P, Jones CM, et al. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer. Ann Oncol. 2017;28(9):2272–2277.
- Markus R, McBride HJ, Ramchandani M, et al. A review of the totality of evidence supporting the development of the first adalimumab biosimilar ABP 501. Adv Ther. 2019;36(8):1833–1850.